Geron/$GERN
1D1W1MYTD1Y5YMAX
Capital at risk
About Geron
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Ticker
- $GERN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 258
- Headquarters
- Foster City, United States
- Website
- www.geron.com
Geron Metrics
BasicAdvanced
$803M
-
-$0.10
0.61
-
Price and volume
Market cap
$803M
Beta
0.61
52-week high
$2.01
52-week low
$1.04
Average daily volume
9.9M
Financial strength
Current ratio
6.915
Quick ratio
5.038
Long term debt to equity
0.554
Total debt to equity
0.559
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
-34.799
Gross margin (TTM)
58.50%
Net profit margin (TTM)
-33.05%
Operating margin (TTM)
-17.25%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-28.28%
Valuation
Price to revenue (TTM)
4.086
Price to book
3.67
Price to tangible book (TTM)
3.67
Price to free cash flow (TTM)
-7.283
Free cash flow yield (TTM)
-13.73%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
24.39%
Earnings per share change (TTM)
-23.63%
3-year revenue growth (CAGR)
668.90%
10-year revenue growth (CAGR)
18.80%
3-year earnings per share growth (CAGR)
-34.58%
10-year earnings per share growth (CAGR)
29.57%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Analyst projections of the future price of Geron stock.
Bulls say / Bears say
RYTELO demand is building rather than stalling. Q2 net product revenue reached a record $57.5 million, up 11% quarter on quarter, ordering accounts rose about 8% to roughly 1,575, and management expects 2026 revenue towards the midpoint to high end of its $220 million-$240 million range. (Geron Corporation, MarketBeat)
The business is moving towards operating leverage. First-half revenue grew 24% year on year while operating expenses fell 4%, and the company ended June with about $327 million in cash, restricted cash and marketable securities. (Geron Corporation, StockAnalysis)
RYTELO has several potential growth paths beyond its current US indication. Real-world LR-MDS evidence was generally consistent with the pivotal study, while European commercialisation and a positive interim myelofibrosis result could add value beyond the current revenue base. (Geron Corporation, StockAnalysis)
Geron remains heavily dependent on one product: RYTELO provides virtually all revenue, with no second commercial product to cushion weaker uptake. That leaves the company exposed to competition, reimbursement pressure and any safety or manufacturing problem. (StockTitan, Longbridge)
The sales ramp has not yet removed cash and margin risk. Q2 included sizeable inventory-related costs, a $16.7 million net loss and cash falling from $341 million to about $327 million, while gross-to-net deductions rose to 20.7%. (Longbridge, Geron Corporation)
The myelofibrosis upside is still a high-risk clinical bet. IMpactMF uses overall survival as its primary endpoint, Geron’s base case is a final analysis in the second half of 2028, and the possible interim path depends on ongoing regulatory discussions and a potential change to the event threshold. (StockAnalysis, Longbridge)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Geron News
AllArticlesVideos
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
MarketBeat2 weeks ago
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Business Wire2 weeks ago
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
MarketBeat2 weeks ago
Funds containing Geron
AllEURUSDGBP
Fund name | Fund size | $GERN weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.07% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.